Antitumor activity observed in a phase I drug–drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC).
Year: 2011
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: T. K. Choueiri, S. K. Pal, M. E. Cabanillas, D. A. Ramies, L. Tseng, J. S. Holland, S. Morrissey, J. P. Dutcher
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2589897609